Walleye Capital
RVMD icon

Walleye Capital’s Revolution Medicines RVMD Stock Holding History

Walleye Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,602
Closed -$3.07M – 5115
2026
Q1 		$3.07M Buy
+31,602
New +$3.19M 0.01% 1132
2025
Q2 		– Sell
-40,340
Closed -$1.43M – 4967
2025
Q1 		$1.43M Sell
40,340
-172,316
-81% -$6.99M 0.01% 1699
2024
Q4 		$9.3M Sell
212,656
-111,076
-34% -$5.61M 0.02% 673
2024
Q3 		$14.7M Buy
323,732
+99,589
+44% +$4.34M 0.03% 487
2024
Q2 		$8.7M Buy
224,143
+189,186
+541% +$7.07M 0.02% 862
2024
Q1 		$1.13M Buy
+34,957
New +$1.04M ﹤0.01% 2478
2023
Q4 		– Sell
-95,517
Closed -$2.64M – 5436
2023
Q3 		$2.64M Buy
+95,517
New +$2.83M 0.01% 1517
2022
Q4 		– Sell
-13,520
Closed -$267K – 3570
2022
Q3 		$267K Buy
+13,520
New +$297K 0.01% 1914

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Walleye Capital's RVMD Position: Q2 2026 in Review

Walleye Capital sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 31,602 shares — an estimated $3.07M sold.

Walleye Capital first reported a position in RVMD in Q3 2022 and held it in 8 quarters. The position peaked at $14.7M in Q3 2024. 692 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Walleye Capital reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 31,602 Revolution Medicines shares in Q2 2026, an estimated $3.07M.
  • Walleye Capital first reported a position in Revolution Medicines in Q3 2022 and held it in 8 quarters.
  • Walleye Capital's Revolution Medicines position peaked at $14.7M in Q3 2024.
  • 692 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.